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FAECAL TRANSPLANTS
Obstacles to establishing an NHS faecal transplant
programme
Benjamin H Mullish clinical research fellow, Horace R T Williams consultant gastroenterologist and
honorary senior lecturer
Division of Digestive Diseases, Faculty of Medicine, Imperial College London, St Mary’s Hospital, London W2 1NY, UK
Having recently established a faecal microbiota transplantation
(FMT) programme, we raise two points about Spector and
Knight’s editorial on FMT.1
Firstly, despite the UK’s relatively permissive regulatory
framework on FMT, we encountered considerable obstacles to
establishing an NHS programme. Donor screening is expensive
(>£500 (€703; $755)/screen/donor, repeated regularly). It is
unclear whether FMT governance falls under the remit of
microbiology, gastroenterology, or pharmacy. There is
reluctance to transfer patients with recurrentClostridium difficile
infection into an FMT centre because of infection control
implications; conversely, clinicians from FMT centres may
encounter difficulties taking transplant material to other hospitals
owing to lengthy administrative processes—for example, issuing
honorary contracts.
Similar difficulties are described elsewhere,2 and theymay result
in FMT not being available to patients who might benefit
greatly. Regional FMT networks could be one solution, with a
“hub” centre to coordinate donors and transplant preparation
and “spoke” centres that have agreed protocols with the hub
centre on FMT delivery.
Secondly, despite the interest in the therapeutic implications of
FMT in a range of conditions, the exact mechanisms by which
it works remain unclear.3 Because FMT treats C difficile
infection so effectively in most cases, analysis of the few donors
whose stool does not induce remission of infection may be
particularly useful. To make scientific advances, researchers
need access to donors for sample analysis and robust clinical
records of outcomes from FMT for each donor; this should be
borne in mind as “stool banks” become established.
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